The Cytokine IL-17A Limits Th17 Pathogenicity Via a Negative Feedback Loop Driven by Autocrine Induction of IL-24.

Wai Po Chong,Mary J. Mattapallil,Kumarkrishna Raychaudhuri,So Jin Bing,Sihan Wu,Yajie Zhong,WeiWei Wang,Zilin Chen,Phyllis B. Silver,Yingyos Jittayasothorn,Chi-Chao Chan,Jun Chen,Reiko Horai,Rachel R. Caspi
DOI: https://doi.org/10.1016/j.immuni.2020.06.022
IF: 32.4
2020-01-01
Immunity
Abstract:Dysregulated Th17 cell responses underlie multiple inflammatory and autoimmune diseases, including autoimmune uveitis and its animal model, EAU. However, clinical trials targeting IL-17A in uveitis were not successful. Here, we report that Th17 cells were regulated by their own signature cytokine, IL-17A. Loss of IL17A in autopathogenic Th17 cells did not reduce their pathogenicity and instead elevated their expression of the Th17 cytokines GM- CSF and IL-17F. Mechanistic in vitro studies revealed a Th17 cell-intrinsic autocrine loop triggered by binding of IL-17A to its receptor, leading to activation of the transcription factor NF-kappa B and induction of IL-24, which repressed the Th17 cytokine program. In vivo, IL-24 treatment ameliorated Th17-induced EAU, whereas silencing of IL-24 in Th17 cells enhanced disease. This regulatory pathway also operated in human Th17 cells. Thus, IL-17A limits pathogenicity of Th17 cells by inducing IL-24. These findings may explain the disappointing therapeutic effect of targeting IL-17A in uveitis.
What problem does this paper attempt to address?